Tekla Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $73.5M | Buy |
545,629
+34,030
| +7% | +$4.99M | 2.88% | 9 |
|
|
2023
Q1 | $81.5M | Buy |
511,599
+33,257
| +7% | +$5.08M | 3.1% | 8 |
|
|
2022
Q4 | $77.3M | Sell |
478,342
-48,500
| -9% | -$7.44M | 2.92% | 8 |
|
|
2022
Q3 | $70.7M | Sell |
526,842
-40,000
| -7% | -$5.74M | 2.89% | 9 |
|
|
2022
Q2 | $86.8M | Buy |
566,842
+18,698
| +3% | +$2.86M | 3.41% | 6 |
|
|
2022
Q1 | $88.9M | Buy |
548,144
+38,327
| +8% | +$5.57M | 3.12% | 7 |
|
|
2021
Q4 | $69M | Sell |
509,817
-14,396
| -3% | -$1.7M | 2.22% | 12 |
|
|
2021
Q3 | $56.5M | Sell |
524,213
-93,090
| -15% | -$10.6M | 1.82% | 15 |
|
|
2021
Q2 | $69.5M | Sell |
617,303
-2,456
| -0.4% | -$277K | 2.26% | 13 |
|
|
2021
Q1 | $67.1M | Hold |
619,759
| – | – | 2.31% | 11 |
|
|
2020
Q4 | $66.4M | Sell |
619,759
-254,961
| -29% | -$24.5M | 2.33% | 9 |
|
|
2020
Q3 | $76.6M | Buy |
874,720
+340,995
| +64% | +$32.1M | 2.87% | 8 |
|
|
2020
Q2 | $52.4M | Buy |
533,725
+192,809
| +57% | +$17M | 1.99% | 12 |
|
|
2020
Q1 | $26M | Hold |
340,916
| – | – | 1.17% | 20 |
|
|
2019
Q4 | $30.2M | Sell |
340,916
-59,100
| -15% | -$4.91M | 1.14% | 22 |
|
|
2019
Q3 | $30.3M | Buy |
400,016
+66,700
| +20% | +$4.57M | 1.32% | 17 |
|
|
2019
Q2 | $24.2M | Buy |
333,316
+13,103
| +4% | +$1.03M | 0.99% | 25 |
|
|
2019
Q1 | $25.8M | Sell |
320,213
-171,865
| -35% | -$14.1M | 1.05% | 25 |
|
|
2018
Q4 | $45.4M | Hold |
492,078
| – | – | 1.94% | 13 |
|
|
2018
Q3 | $46.5M | Sell |
492,078
-21,580
| -4% | -$2.05M | 1.69% | 14 |
|
|
2018
Q2 | $47.6M | Buy |
513,658
+62,920
| +14% | +$6.14M | 1.81% | 14 |
|
|
2018
Q1 | $42.7M | Buy |
450,738
+104,425
| +30% | +$11.5M | 1.66% | 16 |
|
|
2017
Q4 | $33.5M | Buy |
346,313
+241,800
| +231% | +$22.8M | 1.29% | 20 |
|
|
2017
Q3 | $9.29M | Buy |
104,513
+104,300
| +48,967% | +$7.94M | 0.33% | 58 |
|
|
2017
Q2 | $15K | Buy |
213
+57
| +37% | +$3.83K | ﹤0.01% | 144 |
|
|
2017
Q1 | $10K | Hold |
156
| – | – | ﹤0.01% | 139 |
|
|
2016
Q4 | $10K | Hold |
156
| – | – | ﹤0.01% | 143 |
|
|
2016
Q3 | $10K | Hold |
156
| – | – | ﹤0.01% | 142 |
|
|
2016
Q2 | $10K | Hold |
156
| – | – | ﹤0.01% | 156 |
|
|
2016
Q1 | $9K | Hold |
156
| – | – | ﹤0.01% | 140 |
|
|
2015
Q4 | $9K | Sell |
156
-164,000
| -100% | -$9.45M | ﹤0.01% | 134 |
|
|
2015
Q3 | $8.93M | Buy |
164,156
+164,000
| +105,128% | +$10.7M | 0.32% | 72 |
|
|
2015
Q2 | $10K | Sell |
156
-1,110,458
| -100% | -$72.5M | ﹤0.01% | 116 |
|
|
2015
Q1 | $65M | Buy |
1,110,614
+516,395
| +87% | +$31.2M | 2.58% | 9 |
|
|
2014
Q4 | $38.9M | Buy |
594,219
+113,000
| +23% | +$7.12M | 1.82% | 15 |
|
|
2014
Q3 | $27.8M | Buy |
+481,219
| New | +$26.7M | 1.3% | 22 |
|
Other funds holding ABBV
Tekla Capital Management's ABBV Position: Q2 2023 in Review
Tekla Capital Management increased its AbbVie (ABBV) stake by 6.7% in Q2 2023, buying an estimated $4.99M and bringing the position to 545,629 shares worth $73.5M. The position accounts for 2.88% of the portfolio, ranked #9.
Tekla Capital Management first reported a position in ABBV in Q3 2014 and has held it in 36 quarters since. The position peaked at $88.9M in Q1 2022. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.
- Tekla Capital Management held 545,629 shares of AbbVie worth $73.5M as of Q2 2023.
- Tekla Capital Management bought 34,030 AbbVie shares in Q2 2023, an estimated $4.99M.
- AbbVie made up 2.88% of Tekla Capital Management's portfolio in Q2 2023, its #9 holding.
- Tekla Capital Management first reported a position in AbbVie in Q3 2014 and has held it in 36 quarters since.
- Tekla Capital Management's AbbVie position peaked at $88.9M in Q1 2022.
- 3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.